• Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified).

• Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.

• Participants must be able to comprehend English or Spanish (for survey completion).

• Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.

• Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.

• Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey

• In the treating provider's opinion, the participant should have a life expectancy of \>=6 months. Participants in hospice are not eligible.

⁃ Optional Sub-study (available at select sites only):

• Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).

• Must be receiving treatment at the WF CCC and VCU.

• Must be diagnosed with non-small cell lung cancer.

• Must be planning to receive paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) PD-1, PD-L1 or CTLA-4.